We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.53B
1-Year Est. Return 154.61%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+154.61%
3 Year Est. Return
+564.07%
5 Year Est. Return
+985.88%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$441M
Cap. Flow
+$174M
Cap. Flow %
6.85%
Top 10 Hldgs %
44.81%
Holding
120
New
30
Increased
23
Reduced
22
Closed
28

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$84.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$57.5M
3
EW icon
Edwards Lifesciences
EW
+$38.1M
4
ABT icon
Abbott
ABT
+$36.5M
5
UNH icon
UnitedHealth
UNH
+$31.5M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$49.3M
2
BTSG icon
BrightSpring Health Services
BTSG
+$38.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$30.6M
4
CNC icon
Centene
CNC
+$18.7M
5
FMS icon
Fresenius Medical Care
FMS
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.27%
2 Miscellaneous 3.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMS icon
101
Fresenius Medical Care
FMS
$12.1B
– –
-775,000
Closed -$17.5M
GILD icon
102
Gilead Sciences
GILD
$187B
– –
-100,000
Closed -$13.9M
IMCR icon
103
Immunocore
IMCR
$1.61B
– –
-100,000
Closed -$3.02M
IONS icon
104
Ionis Pharmaceuticals
IONS
$7.4B
– –
-125,000
Closed -$9.41M
IQV icon
105
IQVIA
IQV
$44.5B
– –
-35,000
Closed -$5.97M
IRON icon
106
Disc Medicine
IRON
$2.5B
– –
-170,000
Closed -$10.9M
ISRG icon
107
Intuitive Surgical
ISRG
$143B
– –
-35,000
Closed -$16.1M
MLYS icon
108
CALL
Mineralys Therapeutics
MLYS
$2.29B
– –
-500,000
Closed -$13.5M
NRIX icon
109
Nurix Therapeutics
NRIX
$2.39B
– –
-700,000
Closed -$10.8M
PTGX icon
110
Protagonist Therapeutics
PTGX
$9.18B
– –
-50,000
Closed -$5.27M
RVMD icon
111
CALL
Revolution Medicines
RVMD
$43.9B
– –
-500,000
Closed -$48.6M
SLNO
112
DELISTED
Soleno Therapeutics
SLNO
– –
-325,000
Closed -$10.9M
SNDX icon
113
Syndax Pharmaceuticals
SNDX
$1.63B
– –
-350,000
Closed -$8.18M
TARS icon
114
Tarsus Pharmaceuticals
TARS
$3.54B
– –
-200,000
Closed -$14M
TMO icon
115
Thermo Fisher Scientific
TMO
$250B
– –
-20,000
Closed -$9.83M
UNCY icon
116
Unicycive Therapeutics
UNCY
$131M
– –
-225,000
Closed -$1.48M
VKTX icon
117
Viking Therapeutics
VKTX
$4.15B
– –
-250,000
Closed -$8.13M
ZBH icon
118
Zimmer Biomet
ZBH
$17.4B
– –
-50,000
Closed -$4.52M
MAZE
119
Maze Therapeutics
MAZE
$1.45B
– –
-100,000
Closed -$2.98M
EVMN
120
Evommune Inc
EVMN
$308M
– –
-225,000
Closed -$5.17M
1 2 3 4
5

Similar funds

VWA
Visionary Wealth Advisors O'fallon, Illinois $2.53B AUM 24.4% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.54B AUM 18.96% 1-Year Est. Return
QT
Quantbot Technologies New York $2.54B AUM 22.25% 1-Year Est. Return
LMIM
Lockheed Martin Investment Management Bethesda, Maryland $2.53B AUM 37.62% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.54B AUM 23.56% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.54B AUM 17.62% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.52B AUM 26.26% 1-Year Est. Return

Integral Health Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Integral Health Asset Management held 120 positions worth $2.53B, up 21% from $2.09B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $174M of net new capital in Q2 2026, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Abbott: 400,000 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BrightSpring Health Services, an estimated $38.9M trimmed.

  • Integral Health Asset Management's largest Q2 2026 buy was Abbott: 400,000 shares worth $36.3M.
  • Integral Health Asset Management added most to CVS Health in Q2 2026, an estimated $84.8M increase.
  • Integral Health Asset Management's biggest Q2 2026 reduction was BrightSpring Health Services, cutting an estimated $38.9M.
  • Integral Health Asset Management fully exited AstraZeneca in Q2 2026, selling an estimated $49.3M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $2.53B portfolio in Q2 2026.
  • Integral Health Asset Management opened 30 new positions and closed 28 in Q2 2026.
  • Integral Health Asset Management's portfolio value rose 21% quarter-over-quarter to $2.53B.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.